Teva-Kowa Accelerates Japanese Generic Expansion With Taisho Acquisition
This article was originally published in PharmAsia News
Executive Summary
Teva-Kowa Pharma announced Dec. 24 it will purchase a majority stake in mid-size generic competitor Taisho Pharmaceutical Industries. The acquisition gives the joint venture immediate access to 220 generic products and 50 sales staff
You may also be interested in...
Sanofi-Aventis Reportedly In Talks With Nichi-Iko, Could Make Big Splash In Biosimilars
Toyama-based generics manufacturer Nichi-Iko is reported to be in collaboration talks with Sanofi-Aventis to expand both companies' generic drug business in Japan, including a joint effort to tap into Japan's potential follow-on biologics market
Sanofi-Aventis Reportedly In Talks With Nichi-Iko, Could Make Big Splash In Biosimilars
Toyama-based generics manufacturer Nichi-Iko is reported to be in collaboration talks with Sanofi-Aventis to expand both companies' generic drug business in Japan, including a joint effort to tap into Japan's potential follow-on biologics market
Teva-Kowa To Commence Marketing Generics In Japan In January
TOKYO - Teva-Kowa Pharma, a ¥360 million 50-50 joint venture of Teva - the world's largest generics manufacturer - and Japan's diversified manufacturer group Kowa, Dec. 16 said it would commence marketing generic drugs in Japan beginning in January, a few months ahead of schedule